{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-066572","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-05-27T10:37:49+00:00","discovered_at":"2026-05-27T10:40:00.300545+00:00","generated_at":"2026-05-27T10:40:38.486994+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apogee reports positive Phase 2 Part B data for zumilokibart; mid-dose 65.9% EASI-75 vs 23.4% placebo","bullets":["Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.","Key secondary endpoints: IGA 0/1 46.0%, EASI-90 47.4%, I-NRS≥4 50.5% (all p<0.001).","Safety consistent with class; conjunctivitis rate for mid-dose 10.6% vs 15.1% low and 20.7% high.","Plans to initiate Phase 3 ADventure trials in 2H 2026; also Phase 2b asthma and Phase 2a EoE trials.","Blackstone Life Sciences strategic financing collaboration announced to fund through commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066572","json":"https://secwatch.observer/filing/0001104659-26-066572.json","markdown":"https://secwatch.observer/filing/0001104659-26-066572.md","text":"https://secwatch.observer/filing/0001104659-26-066572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/0001104659-26-066572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/tm2615568d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T10:40:38.486994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063161","ticker":"OPTU","company_name":"Optimum Communications, Inc.","filed_at":"2026-06-01T12:16:33+00:00","headline":"Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt","event_type":"other_material","sec_items":["1.01","3.02","7.01","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063161","json":"https://secwatch.observer/filing/0001213900-26-063161.json","markdown":"https://secwatch.observer/filing/0001213900-26-063161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/0001213900-26-063161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/ea0292871-8k_optimum.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068604","ticker":"NXTC","company_name":"NextCure, Inc.","filed_at":"2026-06-01T12:10:58+00:00","headline":"NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068604","json":"https://secwatch.observer/filing/0001104659-26-068604.json","markdown":"https://secwatch.observer/filing/0001104659-26-068604.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/0001104659-26-068604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249763","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2026-06-01T11:55:09+00:00","headline":"Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249763","json":"https://secwatch.observer/filing/0001193125-26-249763.json","markdown":"https://secwatch.observer/filing/0001193125-26-249763.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/0001193125-26-249763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/d124589d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249725","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-06-01T11:30:25+00:00","headline":"Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249725","json":"https://secwatch.observer/filing/0001193125-26-249725.json","markdown":"https://secwatch.observer/filing/0001193125-26-249725.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm"},"side_by_side_evidence":null},{"accession":"0002007587-26-000071","ticker":"AII","company_name":"American Integrity Insurance Group, Inc.","filed_at":"2026-06-01T20:31:10+00:00","headline":"American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002007587-26-000071","json":"https://secwatch.observer/filing/0002007587-26-000071.json","markdown":"https://secwatch.observer/filing/0002007587-26-000071.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/0002007587-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/aii-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}